CommentaryClinical Trials Accrual to Cancer Clinical Trials in the Era of Molecular Medicine Richard L. SchilskySection of Hematology-Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL 60637, USA.E-mail: rschilsk{at}medicine.bsd.uchicago.edu See allHide authors and affiliations Science Translational Medicine 23 Mar 2011:Vol. 3, Issue 75, pp. 75cm9DOI: 10.1126/scitranslmed.3001712 Richard L. Schilsky Find this author on Google Scholar Find this author on PubMed Search for this author on this site Article Figures & Data Info & Metrics eLetters PDF Download PDF You are using an old browser, click here to download PDF PDF Container View Full Text
Accrual to Cancer Clinical Trials in the Era of Molecular Medicine By Richard L. Schilsky Science Translational Medicine23 Mar 2011 : 75cm9 In the testing of targeted cancer therapies, new issues can complicate the decision by patients or providers to participate in clinical trials.
Accrual to Cancer Clinical Trials in the Era of Molecular Medicine By Richard L. Schilsky Science Translational Medicine23 Mar 2011 : 75cm9 In the testing of targeted cancer therapies, new issues can complicate the decision by patients or providers to participate in clinical trials.